On the morning of March 28, the joint opening ceremony of Zhejiang Nuvalve Medical Technology Co., Ltd. and Zhejiang Huancheng Medical Technology Co., Ltd., two leading scientific and technological innovation enterprises in the field of domestic cardiovascular interventional treatment and artificial heart, was held at Haining Juanhu International Sci-Tech City.

NewMed Medical is a Chinese heart valve device company developing interventional products for the treatment of structural heart diseases. It has established a comprehensive product portfolio, including one core product and eight other valve-related products under development. These encompass transcatheter replacement and repair products for human heart valves, as well as seven auxiliary devices for interventional cardiac surgery.

With the successful launch of Prizvalve, NouMed has made a solid step in the cardiac valve treatment field. This not only represents a historic leap for China's cardiac valve sector but also signifies another victory in the journey of domestic substitution. Currently, NouMed has applied for 476 patents covering key areas such as cardiac valves and heart failure treatment devices. The company has also established joint laboratories with several prestigious universities and hospitals across China, promoting innovation at the intersection of medicine and engineering.

HuanQing Medical was founded in 2022, focusing on the development of artificial heart systems. It has broken through global technological barriers such as implantable hollow cup motors and intelligent feedback control, accumulating over 100 patents. Its products have been used in more than 50 cases across more than 10 top-tier hospitals nationwide, receiving excellent clinical feedback. The company is dedicated to the research, development, and industrialization of advanced cardiovascular circulation support products and related auxiliary devices internationally. It aims to restore cardiac function, stabilize cardiovascular hemodynamics, and treat cardiac pumping dysfunction by providing circulatory support. This endeavor fills the gap in domestic products of this kind and meets the huge market demand.

Huanqing Medical's self-developed percutaneous ventricular assist device (pVAD) is an innovative medical device that treats acute heart failure through minimally invasive intervention. It is primarily used for intraoperative support during high-risk percutaneous coronary intervention (PCI) procedures, as well as for the treatment of cardiogenic shock caused by conditions such as acute myocardial infarction and fulminant myocarditis.

The product can maintain hemodynamic stability by sustaining mean arterial pressure in a short period, extract blood from the left ventricle, and pump it back to the aorta, thereby reducing the load on the left ventricle, actively increasing cardiac output, and greatly improving patient survival rates.